Exchange: NASDAQ·Updated 07:30 PM EST
TVTX logo

TVTX Travere Therapeutics Inc

$47.29
$1.30
(2.69%)
Today
Closed $47.00
$0.29
(0.62%)
After Hours
Reported EarningsNov 2
Mkt Cap$4.51B
Vol1.33M

About TVTX

Travere Therapeutics, Inc. is a biopharmaceutical company, which engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
46

Neutral Sentiment

How do you feel about TVTX?

MondrianCoffeeMug
$TVTX Sales and Earnings were actually good. The one-time IPR&D won't become a future expense; remove that and its great. It looks like they are GIA and developing their pipeline with Civo and Phase 3 Peg. Positive long term but patience required. I wonder if they will get back to $60 soon and what analyst re-ratings will be in next few days . I'm not as positive as after Q2, but they're focusing where Im expecting them to.
4
Buckeyeboy722
$TVTX Bank of America increased their position by 1.5 million shares last quarter to 6.8 million total shares. They are includes with Blackrock 8 million shares, Fidelity 5.7 million shares, Vanguard 4.1 million shares, Janus Henderson 11.3 million shares.
2
DeadInvestor
$TVTX Some positive thinking: 2,000 PSFs per quarter, annually is 8,000 per year. After 3 years, that’s 24,000. Assuming net $133K per script on average (IgAN less so, FSGS more so), that’s north of $3 billion in revs. There will be some cancellations throughout of course, but the point is, the current rate gets to $3 billion easily, well before 2033. Travere is a prime acquisition target.
2
DeadInvestor
$TVTX Annual revenues are at $880 million run rate at 90%+ gross margins and yet the company is losing money. There are too many employees. One approved drug with two indications doesn’t need this infrastructure. Sell the company to a large pharma who can absorb this overhead.
1
DeadInvestor
$TVTX Any predictions for tmrw’s print? Can revs exceed $200M? Can PSFs exceed 2,000 again? Will they curtail the SG&A and R&D spend?
1
Meigs1865
$TVTX this looks like a repeat of yesterday, low volume big dip and then a recovery for the rest of the day until closing.
Meigs1865
$TVTX Volume is running at half the daily average with 3 hours to closing of the market. No reason for this beatdown other than the overall market reaction to AI and Data Center nonsense by Democrat Socialsts spewing nonsense.
shoc24
$TVTX reported earnings today after the close and missed EPS estimates: -$0.31 adjusted EPS vs -$0.0984 expected, according to Stock Meadow.
StocktwitsEarnings
$TVTX Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.31 down -152.54% YoY • Reported revenue of $224.56M up 36.21% YoY
shoc24
$TVTX reports earnings today after the close. I used Stock Meadow's earnings dashboard to review its history: TVTX has beaten EPS estimates in 5 of its last 8 reports.
Merlintrader
$TVTX — Q3 results on 2 Nov after the close. Information only — not investment advice. More details in our hub.

Advertisement|Remove ads.